Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Yilport in connection with Infranode’s investment in Yilport Sweden
Mandate

Vinge advises Yilport in connection with Infranode’s investment in Yilport Sweden

April 03, 2019 Banking and Finance

Vinge has advised Yilport Holding AS and Yilport Sweden Terminal Investments AB (“Yilport Sweden”) in connection with a SEK 400,000,000 investment in Yilport Sweden by Infranode I (NO. 1) AB.

Yilport Sweden and its subsidiaries conduct business, inter alia, as port operator of the Port of Gävle and were, prior to the investment, wholly owned subsidiaries of Yilport Holding AS.

Vinge’s team consisted primarily of Albert Wållgren, André Isacson and Stephanie Stiernstedt (Banking and Finance) as well as Matthias Pannier, Rasmus Perdahl, Elsie Nassar and Hannes Pettersson (M&A).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026